Summary of AtaiBeckley's 2026 Investor Day Call Company Overview - **Company**: AtaiBeckley - **Focus**: Development of next-generation psychedelic-based neuroplastogens for mental health treatment, particularly targeting treatment-resistant depression (TRD) and social anxiety disorder (SAD) [1][2] Core Strategies and Pillars - **Mission**: Transform mental health care through rapid-acting, durable, and scalable treatment options [3] - **Four Core Pillars**: 1. Focus on high unmet medical needs (e.g., TRD, SAD) 2. Develop therapies for rapid and durable clinical impact, moving beyond frequent dosing [3] 3. Design products for real-world scalability using familiar administration routes [3] 4. Protect innovations with a comprehensive intellectual property (IP) portfolio [4] Clinical Pipeline - **Lead Asset**: BPL-003, an intranasal dry powder formulation of mebufotenin benzoate, currently in Phase 3 studies for TRD [12][14] - **Other Assets**: - **VLS-01**: Buccal film formulation of DMT for TRD, showing promising Phase 1 results [4][5] - **EMP-01**: Unique MDMA formulation for SAD, with positive Phase 2a results [5] Market Opportunity - **Prevalence**: Over 20 million adults in the U.S. experience major depressive disorder annually, with over 30 million facing social anxiety disorder [6] - **Unmet Needs**: Current treatments often take weeks to show effects and require chronic dosing, leaving many patients without relief [7] Mechanism of Action - **Psychedelic-based Neuroplastogens**: Activate pathways for synaptic regeneration and neurogenesis, disrupting maladaptive brain activity [8] BPL-003 Clinical Data - **Phase 2b Results**: - Statistically significant reduction in MADRS scores at day 29, with effects sustained up to week 8 [18][19] - 8 mg dose showed comparable efficacy to 12 mg with a better safety profile [27] - High response rates, with over 80% in the open-label extension after a second dose [24] Safety and Tolerability - **Adverse Events**: Generally mild to moderate, with a favorable safety profile for the 8 mg dose [25][26] Phase 3 Program - **Design**: Two pivotal trials (ReConnection 1 and 2) to evaluate single and two-dose induction regimens, with a 12-week core study followed by a 52-week open-label extension [28][31] - **FDA Alignment**: Support for the proposed Phase 3 program, including breakthrough therapy designation [12][37] Intellectual Property Strategy - **Comprehensive IP Portfolio**: Protects both composition and method of use claims for BPL-003, with patents extending to 2041 and beyond [39][45] - **Market Exclusivity**: Strategy designed to deter generic competition and ensure commercial viability [48] Commercial Vision - **Market Potential**: TRD market largely untapped, with current treatments reaching less than 3% of eligible patients [49] - **Value Proposition**: BPL-003 offers rapid onset, durable effects, and convenience, addressing barriers to access in mental health care [51][54] - **Economic Model**: Short in-clinic sessions enhance clinic throughput and revenue potential, making the treatment economically viable [59] Conclusion - AtaiBeckley is positioned to lead in the interventional psychiatry space with BPL-003, aiming to reshape treatment paradigms for TRD through innovative, scalable, and effective therapies [12][11]

Core Viewpoint - Atai Beckley N.V. has successfully completed a strategic combination with Beckley Psytech Limited, creating a clinical-stage biopharmaceutical company focused on developing innovative mental health treatments [1][2] Company Overview - AtaiBeckley aims to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments [1][13] - The company is well-financed and Phase 3-ready, with a strong team committed to creating breakthroughs in mental health [2] Pipeline and Development - The lead program, BPL-003, is an investigational nasal spray designed for rapid and durable antidepressant effects, currently being studied for treatment-resistant depression (TRD) [3][5] - BPL-003 has received Breakthrough Therapy designation from the FDA, indicating its potential to significantly improve existing treatments for TRD [3] - The company plans to meet with the FDA for an End-of-Phase 2 meeting to discuss the Phase 3 clinical program design for BPL-003, with studies expected to start in Q2 2026 [4][5] Additional Assets - AtaiBeckley's diversified pipeline includes VLS-01 (DMT buccal film) in Phase 2 for TRD, and EMP-01 (R-MDMA) in exploratory Phase 2a for social anxiety disorder [5] - The company is also developing a portfolio of novel 5-HT2A receptor agonists, including non-hallucinogenic neuroplastogens, in earlier stages [5] Leadership and Governance - The leadership team includes experienced executives from both atai Life Sciences and Beckley Psytech, with Dr. Srinivas Rao as CEO [6][7] - The Board of Directors features accomplished leaders with significant experience in biotechnology and pharmaceuticals, ensuring strong governance [8] Financial Position - In October 2025, Atai closed a public offering that raised approximately $150 million, expected to fund operations into 2029 [9] - The company anticipates this funding will support the first Phase 3 trial of BPL-003 and other ongoing projects [9] Shareholder Approval and Transaction Details - Shareholders approved the strategic combination and redomiciliation to Delaware, with the transaction expected to complete by year-end [10][11] - Approximately 105 million new shares will be issued to Beckley's shareholders, representing about 28% of the combined company [11][12]